Is a mass immunization program for pandemic (H1N1) 2009 good value for money?
Evidence from the Canadian experience
Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, McGeer A, Raboud J, Scales DC, Gojovic MZ, Krahn M

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.vaccine.2010.07.010

Indexing Status
Subject indexing assigned by NLM

MeSH
Cost-Benefit Analysis; Disease Outbreaks /prevention & control; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines /economics; Influenza, Human /prevention & control; Mass Vaccination /economics; Models, Economic; Ontario; Sensitivity and Specificity

AccessionNumber
22010001624

Date bibliographic record published
09/03/2011